On October 8, the US Food and Drug Administration granted Orphan Drug designation to ezepelumab for the treatment of eosinophilic pseudophagitis. Tezepelumab, which is being developed by Astrazeneca and Amgen, is being studied for the treatment of asthma in the US. AZN stock rises 1.65% over the last 2 days. It is trading at $60.78. EoE is a chronic, inflammatory disease caused by the accumulation of eosinophils in the esophagus. This condition can cause chronic pain, weight loss, and malnutrition.
Currently, there is no approved treatment for eosinophilic sclerosingot , which is a rare illness that causes severe symptoms such as pain and difficulty swallowing. Through a clinical study, the company has identified a potential new medicine called tezopelumab that could improve the lives of these individuals. A decision on the Priority Review for tezepelumab in the US is expected in Q1 2022.